Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Nature Reviews Rheumatology

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrrheum.2016.183PMID 27829672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Psoriasis and Psoriatic Arthritis

  2018cited by this paper
• [GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health].

  2018cited by this paper
• New GRAPPA and EULAR recommendations for the management of psoriatic arthritis.

  2017cited by this paper
• Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence

  2017cited by this paper
• Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study

  2016cited by this paper
• Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

  2016cited by this paper
• Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments

  2016cited by this paper
• Mediators of inflammation and bone remodeling in rheumatic disease.

  2016cited by this paper
• GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health.

  2016cited by this paper
• Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments

  2016cited by this paper
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

  2016cited by this paper
• Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP

  2016cited by this paper
• Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

  2015cited by this paper
• Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.

  2015cited by this paper
• Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates

  2015cited by this paper
• Biosimilars in rheumatology: current perspectives and lessons learnt

  2015cited by this paper
• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update

  2015cited by this paper
• Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis?

  2015cited by this paper
• Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis

  2015cited by this paper
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.

  2015cited by this paper
• Clinical Remission in Patients with Active Psoriatic Arthritis Treated with Adalimumab and Correlations in Joint and Skin Manifestations

  2015cited by this paper
• Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score

  2015cited by this paper
• Minimal Disease Activity and Anti–Tumor Necrosis Factor Therapy in Psoriatic Arthritis

  2015cited by this paper
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015

  2015cited by this paper
• Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2015cited by this paper
• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

  2014cited by this paper
• Secukinumab in plaque psoriasis--results of two phase 3 trials.

  2014cited by this paper
• The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment

  2014cited by this paper
• Disease Activity in Psoriatic Arthritis: Comparison of the Discriminative Capacity and Construct Validity of Six Composite Indices in a Real World

  2014cited by this paper
• Drug Therapies for Peripheral Joint Disease in Psoriatic Arthritis: A Systematic Review

  2014cited by this paper
• Remission criteria and activity indices in psoriatic arthritis

  2014cited by this paper
• Systematic Review of Treatments for Psoriatic Arthritis: 2014 Update for the GRAPPA

  2014cited by this paper
• Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

  2014cited by this paper
• Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations

  2014cited by this paper
• SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

  2014cited by this paper
• Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled,

  2014cited by this paper
• Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor

  2014cited by this paper
• Inequities in access to biologic and synthetic DMARDs across 46 European countries

  2013cited by this paper
• Proposal for a new nomenclature of disease-modifying antirheumatic drugs

  2013cited by this paper
• Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force

  2013cited by this paper
• Disparity between ultrasound and clinical findings in psoriatic arthritis

  2013cited by this paper
• Burden of Disease: Psoriasis and Psoriatic Arthritis

  2013cited by this paper
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.

  2013cited by this paper
• Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

  2012cited by this paper
• Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study.

  2012cited by this paper
• A randomized placebo-controlled trial of methotrexate in psoriatic arthritis

  2012cited by this paper
• Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)

  2012cited by this paper
• European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies

  2011cited by this paper
• European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects

  2011cited by this paper
• Faculty Opinions recommendation of A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.

  2011cited by this paper
• A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

  2011cited by this paper
• 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

  2011cited by this paper
• Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data

  2010cited by this paper
• Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort

  2010cited by this paper
• Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis

  2010cited by this paper
• Predictors of response to intra-articular steroid injection in psoriatic arthritis.

  2010cited by this paper
• Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis.

  2010cited by this paper
• Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment

  2009cited by this paper
• Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis

  2009cited by this paper
• Treatment recommendations for psoriatic arthritis

  2008cited by this paper
• Predictors for radiological damage in psoriatic arthritis: results from a single centre

  2006cited by this paper
• Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study.

  2003cited by this paper
• The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

  2001cited by this paper
• A long-term follow-up study

  1997cited by this paper
• Open Access Research Article Risk Factors for Radiographic Progression in Psoriatic Arthritis: Subanalysis of the Randomized Controlled Trial Adept

  year unknowncited by this paper

• LUPUS CO-MORBIDITY IN PATIENTS WITH PSORIATIC ARTHRITIS: A POPULATION-BASED CASE-CONTROLLED STUDY

  2023cites this paper
• Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study

  2022cites this paper
• Prevalence and demographic characteristics of psoriatic arthritis in Colombia: Data from the National Health Registry 2012–2018

  2022cites this paper
• PsABIOnd Study and eDaily Substudy Design: Long-Term Effectiveness and Safety of Guselkumab and IL-17 Inhibitors in Routine Clinical Practice in Patients with Psoriatic Arthritis

  2022cites this paper
• The updated GRAPPA and EULAR recommendations for the management of psoriatic arthritis: similarities and differences.

  2022cites this paper
• Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis.

  2021cites this paper
• Recommendations of the Mexican College of Rheumatology for the management of psoriatic arthritis.

  2021cites this paper
• Psoriatic arthritis

  2021cites this paper
• Is pain associated with premature mortality in patients with psoriatic arthritis? A nested case-control study using the DANBIO Register.

  2021cites this paper
• A dermatologist perspective in the pharmacological treatment of patients with psoriasis and psoriatic arthritis

  2020cites this paper
• Retention rates and identification of factors associated with anti-TNFα, anti-IL17, and anti-IL12/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting

  2020cites this paper
• Epidemiology and Treatment of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis in Germany: A Real-World Evidence Study

  2020cites this paper
• Imaging in the diagnosis and management of axial spondyloarthritis in children.

  2020cites this paper
• Is precision medicine possible in rheumatic diseases? Lessons from selective use of targeted therapies in patients with psoriatic arthritis

  2020influential citation
• Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art

  2020cites this paper
• Metabolic Syndrome and psoriatic arthritis: considerations for the clinician

  2020cites this paper
• Treatment guidelines in psoriatic arthritis

  2020cites this paper
• Doppler enthesitis: a potential useful outcome in the assessment of axial spondyloarthritis and psoriatic arthritis

  2020cites this paper
• Construct validity of the ASAS health index in psoriatic arthritis: a cross-sectional analysis.

  2020cites this paper
• Seminars in Arthritis and Rheumatism

  2020cites this paper
• An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis

  2020cites this paper
• Comment on: ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update’ by Gossec et al

  2020cites this paper
• Differentiating rheumatoid and psoriatic arthritis: a systematic analysis of high-resolution magnetic resonance imaging features—preliminary findings

  2020cites this paper
• Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

  2020cites this paper
• Pathogenesis of psoriasis in the “omic” era. Part IV. Epidemiology, genetics, immunopathogenesis, clinical manifestation and treatment of psoriatic arthritis

  2020cites this paper
• Comparison of remission and low disease activity states with DAPSA, MDA and VLDA in a clinical trial setting in psoriatic arthritis patients: 2-year results from the FUTURE 2 study.

  2020cites this paper
• EULAR PsA management recommendations 2019: can the recommendations be improved?

  2020cites this paper
• Acupuncture for pain management in pediatric psoriatic arthritis: a case report

  2020cites this paper
• Introduction of a Simplified Psoriatic Arthritis Magnetic Resonance Imaging Score (sPsAMRIS): A Potential Tool for Treatment Monitoring in Peripheral Psoriatic Arthritis

  2020cites this paper
• Compromiso Axial en Artritis Psoriásica. Análisis de sus característica en grupo de pacientes con diagnóstico temprano en Sudamérica.

  2020cites this paper
• Actualización en terapia biológica para psoriasis y artritis psoriática (parte I): moléculas pequeñas, inhibidores de JAK y agentes biológicos (inhibidores IL-17)

  2020cites this paper
• Polarized Light Therapy versus Betamethasone Phonophoresis in Treatment of Psoriasis

  2020cites this paper
• Psoriatik artritin tedavisinde yeni ilaçların karşılaştırması

  2019cites this paper
• Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta‐analysis and GRADE evaluation

  2019cites this paper
• French guidelines on the use of systemic treatments for moderate‐to‐severe psoriasis in adults

  2019cites this paper
• Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine

  2019cites this paper
• How Important Are the Standard Measures in Assessing the Clinical Outcomes in Psoriatic Arthritis in Real-world Settings?

  2019cites this paper
• Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis

  2019cites this paper
• [French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults].

  2019cites this paper
• SAT0369 SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR

  2019cites this paper
• SAT0370 IMBALANCE OF TH17 AND REGULATORY T CELLS IN PATIENTS WITH PSORIATIC ARTHRITIS AND RE-BALANCE BY LOW-DOSE IL-2

  2019cites this paper
• AB0788B RECOMENDATIONS FOR DISEASE ACTIVITY ASSESSMENT AND DEFINITION OF CLINICAL REMISSION IN PSORIATIC ARTHTITIS: A DELPHI-BASED EXPERT CONSENSUS

  2019cites this paper
• SAT0371 CARDIOVASCULAR IMPACT OF HYPERURICEMIA IN PATIENTS WITH PSORIATIC ARTHRITIS

  2019cites this paper
• AB0789 AN EHEALTH TOOL TO PREPARE A FIRST ORTHOPAEDIC CONSULTATIONS: A USE AND USABILITY STUDY

  2019cites this paper
• AB0788C PSORIASTIC ARTHRITIS IN PATIENTS DIAGNOSED WITH PSORIASIS ASSISTING DERMATOLOGY CONSULTATION IN A COHORT OF THE DOMINICAN REPUBLIC

  2019cites this paper
• Psoriatic Arthritis: A Current Vision

  2019cites this paper
• Haut trifft Gelenk: Chancen und Herausforderungen der Therapie von Psoriasis und Psoriasis-Arthritis

  2019cites this paper
• Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature.

  2019cites this paper
• Biological and synthetic target DMARDs in psoriatic arthritis.

  2019cites this paper
• Is a simplified version of PsAMRIS (sPsAMRIS) a potential tool for therapy monitoring in established psoriatic arthritis?

  2019cites this paper
• Psoriatic arthritis: tissue-directed inflammation?

  2018cites this paper
• Wissenswertes rund um die Diagnostik

  2018cites this paper
• [Therapy of Psoriasis Arthritis Taking into Account New Treatment Options].

  2018cites this paper
• Auswahl klinischer und diagnostischer Ergebnisse bei entzündlichen Gelenkerkrankungen

  2018cites this paper
• Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives

  2018cites this paper
• Cause‐specific mortality in patients with psoriasis and psoriatic arthritis

  2018cites this paper
• Psoriatic arthritis: new evidence for old concepts

  2018cites this paper
• Defining the osteoarthritis patient: back to the future.

  2018cites this paper
• Long‐term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single‐center experience

  2018cites this paper
• Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial

  2018cites this paper
• Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study

  2018cites this paper
• Safety of treatment options for spondyloarthritis: a narrative review

  2018cites this paper
• Gelenkerkrankungen Selection of Clinical and Diagnostic Results of Inflammatory Joint Diseases

  2018cites this paper
• Syddansk Universitet Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis protocol for a 6-month, double-blind, randomised, placebo-controlled trial Kragsnaes,

  2018cites this paper
• Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

  2018cites this paper
• Prevalence of minimal disease activity in Australian patients with Psoriatic Arthritis: Assessing the outcome of national funding criteria for biologic disease‐modifying antirheumatic drug prescribing

  2018cites this paper
• Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries

  2018cites this paper
• Enthesitis detection by ultrasound: where are we now?

  2018cites this paper
• Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study

  2018cites this paper
• The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis

  2018cites this paper
• Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative

  2018cites this paper
• Ustekinumab in psoriatic arthritis: need for studies from real-world evidence

  2018cites this paper
• Ustekinumab v terapii psoriatické artritidy

  2017cites this paper
• The immunological mechanisms that control pneumococcal carriage

  2017cites this paper
• Secukinumab in treating psoriatic arthritis

  2017cites this paper
• Periodontal Disease and Autoimmunity: What We Have Learned from Microbiome Studies in Rheumatology

  2017cites this paper
• Small molecule therapy for managing moderate to severe psoriatic arthritis

  2017cites this paper
• Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

  2017cites this paper
• Management of psoriatic arthritis among cutaneous psoriasis patients: from pathogenesis to therapy.

  2017cites this paper
• A Review of the Use of Secukinumab for Psoriatic Arthritis

  2017influential citation